Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...
Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode (TM) Whole ...
BostonGene, developer of the leading AI foundation model for tumor and immune biology, announced results from the FEASY study ...
Evaluation of 68Ga-FAPI PET/CT and 18F-FDG PET/CT for the primary staging of non-small cell lung cancer (NSCLC). Application of an epigenomic-based classifier to identify cancer signal of origin on ...
Recent advances in research have focused on immune system variation mainly from a genome perspective. This population-based study (N=1,001 from The Human Phenome Atlas (THPA) cohort) investigated the ...
Using multi-year field trials and transcriptome-wide allele-specific expression analyses, they showed maternal inbred choice can speed seed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results